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Abstract
Both linkage and association studies have been successfully applied to identify disease susceptibility genes with genetic
markers such as microsatellites and Single Nucleotide Polymorphisms (SNPs). As one of the traditional family-based studies,
the Transmission/Disequilibrium Test (TDT) measures the over-transmission of an allele in a trio from its heterozygous
parents to the affected offspring and can be potentially useful to identify genetic determinants for complex disorders.
However, there is reduced information when complete trio information is unavailable. In this study, we developed a novel
approach to ‘‘infer’’ the transmission of SNPs by combining both the linkage and association data, which uses microsatellite
markers from families informative for linkage together with SNP markers from the offspring who are genotyped for both
linkage and a Genome-Wide Association Study (GWAS). We generalized the traditional TDT to process these inferred dosage
probabilities, which we name as the dosage-TDT (dTDT). For evaluation purpose, we developed a simulation procedure to
assess its operating characteristics. We applied the dTDT to the simulated data and documented the power of the dTDT
under a number of different realistic scenarios. Finally, we applied our methods to a family study of alcohol dependence
(COGA) and performed individual genotyping on complete families for the top signals. One SNP (rs4903712 on chromosome
14) remained significant after correcting for multiple testing Methods developed in this study can be adapted to other
platforms and will have widespread applicability in genomic research when case-control GWAS data are collected in families
with existing linkage data.
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Introduction
Linkage studies have been successfully used to identify many
disease genes such as hyper-cholesterolaemia [1–3], Huntington’s
disease [4] and cystic fibrosis [5]. Linkage studies allow direct
observation of recombination events in a family pedigree with a
limited number of generations, as well as simultaneous analysis of
multiple genetic markers. The LOD score (logarithm of odds),
developed by Newton E. Morton [6], is a statistical test often used
for linkage analysis in human. The LOD score compares the
likelihood of obtaining the test data if the two loci are indeed
linked, to the likelihood of observing the same data by chance.
However, this setup requires tailor-made likelihood statistics.
When it comes to a multi-loci model, the situation can be even
more cumbersome [7]. On the other hand, because of the
requirement of a large number of families with several affected
generations, linkage analysis can be less helpful when dealing with
diseases of late-onset with a high mortality. Alternatively,
association studies are used to identify disease susceptibility genes
by comparing genetic variants between individuals with and
without the disease of interest. High-throughput genotyping has
allowed large-scale association studies over the entire human
genome. In 2005, the first Genome-Wide Association Study
(GWAS) was successfully applied on human age-related macular
degeneration [8]. Since then, GWAS has been widely used to
identify the association between genetic variants, typically single-
nucleotide polymorphisms (SNPs), and heritable traits or diseases.
In general, there are two major types of designs that are
commonly used in association research: population-based and
family-based studies. As the most common population-based
approach, the case-control setup compares an unrelated healthy
control group and affected case group. The genotyped SNPs are
investigated to identify the allele frequency differences between
these two groups. The study then determines whether the SNPs
are associated with the genetic trait or disease based on the
statistical significance of the differences. The independent samples
are typically easier to obtain in a case-control study than family
samples. However, many case-control samples select independent
cases from existing family data that were originally used in linkage
analysis. Because cases can be over-sampled from groups with
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higher disease prevalence, the differences of allele frequencies in
an admixture of ethnic groups may produce spurious associations.
Therefore, although case-control studies have shown advantages
in identifying association between the disease susceptibility and
markers in a candidate gene, the results may reflect type I errors
(false-positive) due to unaccounted confounding factors [9–11]
such as population stratification [12–16].
Unlike the population-based studies, family-based studies are
resistant to type I errors arising from population stratification. The
family-based Transmission/Disequilibrium Test (TDT) measures
the over-transmission of an allele from heterozygous parents to
their affected offspring, in which the non-transmitted parental
alleles serve, in effect, as a control group. Therefore the TDT is a
robust test of association in the presence of geographical or
ethnical impact from the population [17]. In the original TDT
[18], a parent-proband trio is considered as a basic unit, in which a
proband is the first affected family member who seeks medical
attention for a genetic disorder. Assuming complete genotype
information for a two allele marker locus in each trio, the TDT
compares the number of heterozygous parents who transmit either
allele to the affected offspring. The TDT can be constructed
through a 2 by 2 table (Table 1). Under the null hypothesis of no
associaton, the proportions b=(bzc) & c=(bzc)are tested against
(0.5, 0.5) using a binomial (asymptotically chi-square) test with one
degree of freedom:
x2~
½b{(bzc)=22
(bzc)=2
z
½c{(bzc)=22
(bzc)=2
~
(b{c)2
bzc
ð1Þ
Because neither genotypes nor allele frequencies are required,
the TDT is considered robust to the population stratification as
mentioned above.
A variety of TDT-like tests have been suggested starting with
Rubinstein et al [19]. Curtis and Sham studied a multi-allelic
TDT with incorporation of missing parents [20,21]. This was
extended by Spielman et al and Horvath et al [22,23] with the
TDT applied to different family structures in their sib-ship tests.
For an allele of interest at a marker locus, the sib-ship test
essentially compares the frequency of that allele among affected
individuals with the frequency of the allele among unaffected
individuals, which allows the TDT to be applied to diseases with
late age of onset, such as non-insulin-dependent diabetes,
cardiovascular diseases, Alzheimer’s disease, and other diseases
related to aging. Several studies also discussed the application of
the TDT for mapping quantitative trait loci [24–30]. Gordon
et al.’s TDTae allows for genotyping errors in the analysis and
accommodates various error models [31]. As discussed above,
multiple affected and unaffected siblings are often collected and
used for both linkage and association analysis. The family-based
association test (FBAT) generalized the TDT model on various
phenotypic traits and multiple markers [32–36]. Instead of using
data from only the heterozygous parents as in the TDT, the
affected-family based controls (AFBAC) method [37] is developed
to take advantage of all the parental information. But the trade-off
of this setup is its vulnerability to population stratification as
genotype frequencies are not irrelevant in this test [37,38].
Another extension of the TDT, the pedigree disequilibrium test
(PDT), is specifically designed for analyzing the Linkage Disequi-
librium (LD, the non-random association of alleles at two or more
loci) in general pedigrees, which has been successfully applied on a
number of complex traits such as diabetes [38,39]. Further, as a
more powerful development to the PDT, the presence of linkage
(APL) is used to handle diseases of late-onset [38,40]. However, in
spite of the divergences as well as the great promise of these TDT-
type analyses [9,24,41], one primary limitation that most of these
extensions encounter is the dependence on completeness of the
genotype information for all trio members in a single test and lack
of scalability on utilizing both the linkage and association data in a
study.
Disorders can often have genotype information from only one
parent of the affected individuals. As a common practice, these
trios are simply discarded [42] though this can result in
considerable loss of information and bias to the association study
[20,38]. Several studies have been proposed to allow TDT to
handle missing parental genotypic information [20,22,43–50].
Within these studies, the missing parental genotypes are mostly
reconstructed based on the assumption that they are missing
completely at random and do not depend on the genotypes
themselves [51]. However, this assumption may not hold true and
the probability that a genotype is missing may rely on the
unobserved alleles [38,52,53]. Furthermore, these approaches are
not designed for pedigrees with missing genotypes on the proband
when both linkage and association data are available.
Against this background, we note this is a two step procedure. In
the first step, the SNP data is used with both parents missing, so
that the analysis depends on external allele frequency estimates
and is sensitive to population stratification. In the second step,
individual genotyping is performed on the parents for the top
SNPs from step one, so this step is a traditional TDT and
insensitive to the potential biases in step one. Accordingly, having
available family DNA is needed to avoid false positive results.
Methods
As stated above, the traditional TDT requires complete
genotypic information from all members of the nuclear families.
However, obtaining all genotypes cannot always be feasible for
some diseases or families. Therefore the traditional TDT-type
studies may not be useful to identify the presence of genetic
determinants in data with relatively small amounts of complete trio
information. One way to solve this type of issue is to reconstruct
the missing parental genotypes under the assumption that they
follow the probability distribution of the fully observed cases.
However, most studies designed for this purpose do not
incorporate the impact from LD and thus may introduce bias to
the results. On the other hand, there are data available that have
genotype information on both microsatellite and SNP markers for
diseases; one example is alcoholism [54]. With both the linkage
and association data, usually the microsatellite genotypic infor-
mation from families for linkage analysis together with SNP data
from the offspring who are genotyped for both linkage and
Table 1. Summary of the original TDT design in a 262 table.
Non-transmitted allele
Transmitted
allele M1 M2 Total
M1 a b a+b
M2 c d c+d
Total a+c b+d 2n
The letters (a, b, c, d) represent the counts of over-transmissions of an allele
from the parents to affected offsprings. The number n denotes total number of
affected offsprings and 2n represents the total number of parents.
doi:10.1371/journal.pone.0063526.t001
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GWAS, we can ‘‘infer’’ the transmission of SNPs for the rest of the
family members who have not been genotyped on SNPs. We call
these family members the ‘‘missing individuals’’. In detail, first we
generate the combined pedigrees in which each individual has
both the linkage and GWAS genotype data filled in. Genotypes
that those individuals do not have will be taken as missing data in
the combined pedigrees. Then we use the program MERLIN [55]
to read these combined pedigrees as input and infer the dosage
probabilities of dense SNP genotypes for these missing individuals
(see section Genotype Inference of Familial Individuals for more details).
All the trio combinations from the inferred pedigrees are extracted
on the condition that the children were affected and at least one
parent in the trio was genotyped on microsatellite markers. The
dosage-TDT that we have developed in this study is applied on
these trio pedigrees using their inferred dosage probabilities. By
incorporating the family linkage information into the GWAS data,
we can potentially have higher power to detect association
between our genotypic markers and the disease susceptibility
alleles.
Dosage Transmission Disequilibrium Test (dTDT)
Common map of both linkage & GWAS data. The
common map of both linkage and GWAS data is designed in the
following way. With the genetic position of the linkage markers
(microsatellite as in here) and physical position of both linkage and
GWAS markers (microsatellite and SNPs), the genetic positions of
all the GWAS markers (SNPs) are calculated based on equation (2):
gmSNPi~
gmMS1{
pmMS1{pmSNP1
106
(pmSNPivpmMS1 )
gmMSjz1{(gmMSjz1{gmMSj )
:
pmMSjz1{pmSNPi
pmMSjz1{pmMSj
(pmMSjvpmSNPivpmMSjz1 ,1ƒjƒlast{1)
gmMSlastz
pmSNPi{pmMSlast
106
(pmSNPiwpmMSlast )
8>>>>><
>>>>>:
ð2Þ
where gm denotes the genetic position of a marker, in centi-Morgan
(cM) unit; pm denotes the physical position of a marker, in base pair
units; MSlast is the last microsatellite marker on a chromosome,
pmMSjz1ƒpmMSlast . Because at both ends of a chromosome when
the physical position of a SNP is either smaller than the 1st
microsatellite marker or larger than the last microsatellite marker,
there is only one microsatellite marker that can be referred to
compute the genetic position for the SNP. We simply use the
convention that 1cM < 106 base pairs to convert a SNP’s physical
map to its genetic map. While a SNP is in between two
microsatellite markers, we use the ratio
pmMSjz1{pmSNPi
pmMSjz1{pmMSj
and
multiply this ratio with the genetic distance between these two
microsatellite markers (gmMSjz1{gmMSj): In this way we compute
the relative genetic position of a SNP marker to the microsatellite
marker that’s next to it.
Genotype inference of familial individuals. Initially, many
approaches implicitly imputed missing genotypes based on the
potential genotype distribution in a family [56–58]. In practice, the
genetic linkage implied that family members share a certain degree of
similarity through their ‘‘identical-by-descent’’ (IBD) regions on the
chromosomes. In this way, genotypes of the non-typed markers for
these family members can be inferred according to their shared IBD
with the other relatives. Figure 1 illustrates the procedure of this
genotype inference. As shown in the figure, a subset of microsatellite
markers has been typed for all the family members except the founders
(red), whereas both microsatellite and SNPmarkers have been typed in
only a few selected common individuals (black). Genotypes of the dense
SNPs for missing individuals can be inferred by comparing the
haplotypes that are IBD with the other individuals in the family.
Several studies have been published on the genotype imputation
procedures described above [59,60]. These procedures are imple-
mented in programs such as MERLIN [55,61] and MENDEL
[62,63], using one of the pedigree analysis algorithms such as the
Lander-Green [64] or Elston-Stewart [65] algorithms, or Monte Carlo
sampling [66,67]. Merlin uses sparse trees to represent gene flow in
pedigrees and is considered as one of the fastest packages among
packages implementing the same algorithms such as Allegro [68] and
Genehunter [69]. In this study, we use MERLIN to infer the dosage
probabilities. The output of this program includes the most likely
genotypes, the expected number of copies for the tested alleles (0, 1, or
2 with genotype observed), and the posterior probabilities (dosage
probabilities) of the three alternative genotypes [70]. Because a large
number of related individuals are included, this family-based genotype
inference is expected to improve the power of association tests [59].
Furthermore, when a GWA scan follows a linkage study, only a
proportion of individuals may need to be genotyped and the inferred
genotypes can be useful for the next step in the association analysis.
Dosage-TDT. Because the traditional TDT is a simple
representation of the x2 statistics, it requires single counts of the
transmitted/non-transmitted alleles from the heterozygous parents
to the affected offspring. Thus the inferred dosage probabilities
cannot be processed through this setup. In this study, we
generalize the original TDT by taking all possible allele
transmissions in a pedigree into account. Table 2 shows the
dosage probabilities of three alternative genotypes (1/1, 1/2 and
2/2) in a trio (named a trio-dosage set in this work) from the inferred
results. Table 3 lists all 11 TDT-informative allele transmissions
in a trio where at least one of the parents is heterozygous. The
values of bi and ci used in the x
2 calculation of the TDT in each
trio i are calculated by summing up the probabilities across all
these 11 types of transmissions. Let t denote the probability that
allele 1 is transmitted by a heterozygote parent of an affected child.
We can then write the dosage probabilities of a child in terms of
the dosage probabilities of its parents and t as follows:
pc11~P(c11D f11,m12):P(f11,m12)zP(c11D f12,m11):P(f12,m11)
zP(c11D f12,m12):P(f12,m12)zP(c11D f11,m11):P(f11,m11)
~pf 11pm12:tzpf 12pm11:tzpf 12pm12:t
2zpf 11pm11
ð3Þ
pc12~P(c12D f11,m12):P(f11,m12)zP(c12D f12,m11):P(f12,m11)z
P(c12D f12,m12):P(f12,m12)zP(c12D f12,m22):P(f12,m22)z
P(c12D f22,m12):P(f22,m12)zP(c12D f11,m22):P(f11,m22)z
P(c12D f22,m11):P(f22,m11)
~pf 11pm12:(1{t)zpf 12pm11:(1{t)z2pf 12pm12:t(1{t)z
pf 12pm22:tzpf 22pm12:tzpf 11pm22zpf 22pm11
ð4Þ
TDT Using Linkage and Association Detection
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pc22~P(c22D f12,m12):P(f12,m12)zP(c22D f12,m22):P(f12,m22)
zP(c22D f22,m12):P(f22,m12)zP(c22D f22,m22):P(f22,m22)
~pf 12pm12:(1{t)
2zpf 12pm22:(1{t)zpf 22pm12:(1{t)zpf 22pm22
ð5Þ
Thus, the frequencies of allele 1 and 2 of a child appearing in a
trio are as follows:
pc1~pc11z
1
2
pc12
~pf 11pm12:
1zt
2
zpf 12pm11:
1zt
2
zpf 12pm12:tzpf 11pm11
zpf 12pm22:
t
2
zpf 22pm12:
t
2
z
1
2
pf 11pm22z
1
2
pf 22pm11
ð6Þ
pc2~
1
2
pc12zpc22
~pf 11pm12:
1{t
2
zpf 12pm11:
1{t
2
zpf 12pm12:(1{t)z
1
2
pf 11pm22
z
1
2
pf 22pm11zpf 12pm22:(1{
t
2
)zpf 22pm12:(1{
t
2
)zpf 22pm22
ð7Þ
Additionally, pc11zpc12zpc22~1 ð8Þ
Based on equations (3) to (8), we can derive that:
t~
(2pc11zpc12){(pf 11zpm11)
pf 12zpm12
ð9Þ
Figure 1. Demonstration of genotype inference within a family. (a) The observed data, which consist of genotypes at a series of microsatellite
and SNP markers. A subset of microsatellite markers has been typed in all individuals except for founders (red), whereas both microsatellite and SNP
markers have been typed in only a few selected common individuals (black). (b) Genotypes of dense SNPs for missing individuals are inferred by
comparing the haplotypes they share with the common individuals.
doi:10.1371/journal.pone.0063526.g001
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In summary, the sum of all 11 informative transmissions for bi
and ci can be written as:
bi~(pf 12zpm12):t ð10Þ
ci~(pf 12zpm12):(1{t) ð11Þ
where i represents the ith trio. By substituting t from equation (9)
into (10) and (11) and summing up bi and ci for all trios, we can
compute the x2 values for each SNP:
x2~
(
P
bi{
P
ci)
2
P
biz
P
ci
ð12Þ
which follows a one degree freedom x2 distribution under the null
hypothesis of no association. We name this generalized TDT the
dosage TDT (dTDT). The original TDT proposed by Spielman
et al [18] can then be considered as a special case when t and the
dosage probabilities in a trio-dosage set is 0 or 1.
The beauty of the above equations is the denominator from t
can be canceled out with the one in bi and ci thus equation (12) can
be further written as:
x2~
½P di{P (zi{di)2P
diz
P
(zi{di)
ð13Þ
in which we denote
di~½(2pc11zpc12){(pf 11zpm11)i ð14Þ
zi~(pf 12zpm12)i ð15Þ
for each trio i. Using form (13) can be computationally efficient.
Simulation
The dTDT makes it possible to process the inferred dosage
probabilities of the un-genotyped SNPs for those missing
individuals in a nuclear family. As a follow-up study of this
generalized TDT approach, we develop a simulation to investigate
how the power changes for association detection with different
inputs. In this simulation, we generate multiple sets of trios under
various settings. Each set has 1,000 trios. Each trio has one
affected child. Because we focus on the interaction between SNP
and microsatellite markers, only one SNP marker and one
microsatellite marker are simulated. In each trio, the microsatellite
markers are assigned to both the parents and the child. SNPs are
only assigned to the child. The parents who do not have such SNP
markers are considered as the missing individuals and their SNP
genotypes are inferred by MERLIN. The dTDT is then used to
process the inferred dosage probabilities and p-values are reported
from the x2 statistics.
Generating SNPs. Denote the low and high risk alleles at a
disease locus D as D1 and D2, with population frequencies p1 and
p2. Assuming Hardy-Weinberg equilibrium, the population
prevalence (K) of the disease is
K~p21f11z2p1p2f12zp
2
2f22 ð16Þ
where f11, f12 and f22 are the penetrances of the three genotypes
D1D1, D1D2 and D2D2.
We have considered three disease models: dominant, recessive
and co-dominant. The combinations of the penetrances in these
three models are designed as follows: dominant (f11,f12 = f22),
recessive (f11 = f12,f22) and co-dominant (f11,f12 =K f22).
With K and f predefined, we can compute p1 and p2 using the
following equations:
p1~
(f22{f12){
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
f 212{f11f22zK
:(f11{2f12zf22)
q
f11{2f12zf22
ð17Þ
p2~1{p1 ð18Þ
Denote the haplotype frequencies of disease locus D and SNP
locus S as h11, h12, h21 and h22. On condition of the child being
Table 2. Dosage probabilities in a trio (denoted as a trio-
dosage set).
Genotype
1/1 1/2 2/2
Father pf11 pf12 pf22
Mother pm11 pm12 pm22
Child pc11 pc12 pc22
doi:10.1371/journal.pone.0063526.t002
Table 3. Calculation of bi and ci in terms of dosage probabilities and t for the i
th trio with all 11 TDT-informative transmissions.
1/1–1/2
|
1/1
1/1–1/2
|
1/2
1/2–1/1
|
1/1
1/2–1/1
|
1/2
1/2–1/2
|
1/1
1/2–1/2
|
1/2
1/2–1/2
|
2/2
1/2–2/2
|
1/2
1/2–2/2
|
2/2
2/2–1/2
|
1/2
2/2–1/2
|
2/2 Sum
bi pf11pm12Nt pf12pm11Nt 2pf12pm12N
t2
2pf12pm12N
t(1-t)
pf12pm22Nt pf22pm12Nt (pf12+pm12) Nt
ci pf11pm12N
(1-t)
pf12pm11N
(1-t)
2pf12pm12N
(1-t)
2pf12pm12N
(1-t)2
pf12pm22N
(1-t)
pf22pm12N
(1-t)
(pf12+pm12) N
(1-t)
t denotes the possibility that allele 1 is transmitted by a heterozygote; and (1-t) is the possibility that allele 2 is transmitted.
doi:10.1371/journal.pone.0063526.t003
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affected, the probabilities of different haplotypes in a child can be
calculated through:
p(H11H11jA)~ f11h
2
11
K
p(H11H12jA)~ 2f11h11h12K
p(H12H12jA)~ f11h
2
12
K
9>>=
>>;
p(H11H21jA)~ 2f12h11h21K
p(H11H22jA)~ 2f12h11h22K
p(H12H21jA)~ 2f12h12h21K
p(H12H22jA)~ 2f12h12h22K
9>>>=
>>>;
ð19Þ
p(H21H21jA)~ f22h
2
21
K
p(H21H22jA)~ 2f22h21h22K
p(H22H22jA)~ f22h
2
22
K
9>>=
>>;
With a predefined correlation coefficient (R) of linkage
disequilibrium (LD) between D and S, we can derive the haplotype
frequencies as follows:
h11~p1q1zR
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p1p2q1q2
p
h12~p1q2{R
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p1p2q1q2
p
h21~p2q1{R
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p1p2q1q2
p
h22~p2q2zR
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p1p2q1q2
p
9>>=
>>;
ð20Þ
where q1 and q2 are the population frequencies of the SNP alleles
S1 and S2. To simplify our model, we will assume pi= qi, where
i=1 or 2. The rationale behind this is that if the SNP marker and
disease allele have very different frequencies, then R2 is small and
there is little power. Keeping both frequencies equal allow R to
vary the full range from 21 to +1.
By substituting (20) into (19), we can assign the genotypes (S1S1,
S1S2, or S2S2) at locus S to the affected children based on these
derived frequencies:
p(S1S1jA)~ f11h11
2z2f12h11h21zf22h21
2
K
p(S1S2jA)~ 2(f11h11h12zf12h11h22zf12h12h21zf22h21h22)K
p(S2S2jA)~ f11h12
2z2f12h12h22zf22h22
2
K
9>>=
>>;
ð21Þ
Generating microsatellites. Denote Mi as the microsatellite
marker from the parents. Because of a large number of
polymorphisms (alleles) for a microsatellite marker, we assume
that our microsatellite marker is completely informative (i.e., each
parent is heterozygous at the microsatellite locus M) and assign
alleles M1 & M2 to the father and M3 & M4 to the mother. Then
we randomly select M1 & M3, M2 & M4, M1 & M4 or M2 & M3
equally with 0.25 probabilities as the microsatellite genotype for
the child.
Parameter settings. Without losing biological meaning, i.e.
with valid pi M(0, 1.0] (i=1 or 2 and p1+ p2 = 1), but also with a
good coverage of possible natural phenomena, we predefine the
following values for the parameters to generate each set of trios:
N: the number of trios = 1,000;
K: prevalence = 0.01, 0.1, or 0.2;
R: correlation coefficient of LD between D and S=0.5, 0.7, 0.9,
or 1.0 (as negative value of R does not produce informative
divergence from the result using positive value of R, we are only
considering positive value of R herewith);
f or g: penetrance of disease genotype DiDi or DiDj, where i or
j=1 or 2 and i ? j. To simplify the notation, here we use f to
denote f11 and g to denote f12 or f22. As noted, we separate the
disease models as dominant (f, g, g), recessive (f, f, g), and co-
dominant (f, 0.5g, g) where f=0.0, 0.1K, 0.3K, 0.5K, 0.7K, or 0.9K
and g=1.1K, 0.5, 0.7, 0.9, or 1.0.
These values are first permuted to generate all their possible
combinations then any combination that produces invalid p,
i.e.p 6 [ (0,1:0, is excluded. Under each setting, we produce 1,000
trios based on equation (15) for SNPs in the affected offsprings.
Parental SNPs are inferred by MERLIN and dTDT is used to
process the inferred dosage probabilities.
Application to Alcohol Dependence
Alcohol dependence is a serious psychiatric disorder in which an
individual is characterized as having harmful consequences of
repeated or compulsive alcohol use, and (sometimes) physiological
dependence on alcohol (i.e., tolerance and/or symptoms of
withdrawal) [71,72]. During 2001–2005, excessive alcohol use
contributed to about 79,000 deaths and 2.3 million years of
potential life lost in the United States [73]. Excessive alcohol
Table 4. Number of total and genotyped individuals, and corresponding number of families that these individuals are selected
from.
Total Individuals
(indtotal)
Number of Genotyped Individuals on
microsatellite markers (indMS) Number of Families
Map03MS EA 2,037 1,926 (94.55%) 219
Map03MS AA 335 283 (84.48%) 35
Map03MS Mixed 87 74 (85.06%) 8
MarshfieldMS EA 1,530 1,090 (71.24%) 234
MarshfieldMS AA 570 347 (60.88%) 77
MarshfieldMS Mixed 6 5 (83.33%) 1
doi:10.1371/journal.pone.0063526.t004
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consumption, the third leading cause of preventable death in the
United States, can cause damage to the central and peripheral
nervous system, and to nearly every organ system in the body
[74,75]. It is reported that alcohol dependence affects about 12%
of American adults across their lifetime [76]. As a complex disease,
alcohol dependence can be influenced by various factors such as
genetic susceptibility, environmental influences and interactions
among genes or between genes and environment.
The nine-site national Collaborative study On the Genetics of
Alcoholism (COGA) funded by National Institute of Alcohol and
Alcoholism (NIAAA) aims to identify and characterize genes that
affect the susceptibility to develop alcohol dependence and related
phenotypes. COGA is applying multiple strategies for genetic
research. The most densely affected, multiplex alcoholic families
were used in a multi-wave family-based linkage study. 2,283 out of
2,459 individuals from 262 families were genotyped using
microsatellite markers in Wave I and Wave II (data denoted as
Map03MS) (Table 4) [54]. At Wave III, another 1,442 out of
2,106 individuals from 312 families were selected for microsatellite
genotyping by the Mammalian Genotyping Service (MGS) from
Marshfield Clinic (data denoted as MarshfieldMS) (Table 4).
Combined data from all three waves are denoted as LinkageMS in
this study. COGA also has high throughput GWAS data with over
1 million SNP markers from 1,884 independent individuals,
generated by the Center for Inherited Disease Research (CIDR)
(data denoted as CIDRSNP) (Edenberg et al., 2010). The GWAS
data include 566 mutual individuals chosen from the LinkageMS
families.
All participants agreed to share their DNA and phenotypic
information for research purposes and provided written informed
consent following instructions from institutional review boards at
all data collection sites. The study was approved by the
institutional review board at each COGA site, with the OHRP
Assurance Numbers being: FWA00003624 (SUNY Research
Foundation), FWA00007125 (University of Connecticut),
FWA00003544 (Indiana University), FWA00003007 (University
of Iowa), FWA00004069 (Veterans Medical Research Founda-
tion/UCSD), FWA00002284 (Washington University),
FWA00003518 (Southwest Foundation for Biomedical Research),
FWA00003913 (Rutgers, The State University of New Jersey) and
FWA00005287 (Virginia Commonwealth University).
As described above, the dTDT uses the inferred dosage
probabilities of dense SNPs for association detection. The COGA
family data provides us such an opportunity to integrate the
information from both linkage and association studies.
In this study, we first generate the combined pedigrees with
both the LinkageMS and CIDRSNP genotype data from COGA.
Figure 2 demonstrates the structure of the combined pedigrees.
Most individuals in the combined pedigrees were genotyped on
microsatellite markers. A subset of individuals in the pedigrees was
genotyped for dense SNPs. These individuals include one affected
child in each of the families and other unrelated members chosen
as a control group. All other individuals who have not been
genotyped on SNPs are considered as the missing individuals. We
use the program MERLIN [55] to read these combined pedigrees
as input and infer the dosage probabilities of dense SNP genotypes
for these missing individuals (described in detail below). All the trio
combinations from the inferred pedigrees are extracted on the
condition that the children were affected and at least one parent in
the trio was genotyped on microsatellite markers. The dTDT is
applied on these trio pedigrees using their inferred dosage
probabilities. In addition, PLINK 77 is used to conduct a standard
case-control study on the CIDRSNP data. With the idea that
making use of all the available sample data would increase the
power for association detection, we further combine the results
from both dTDT and case-control study through the MH test
[78].
Data sets. The Map03MS data have 219 European Amer-
ican (EA), 35 African American (AA) and eight mixed families.
2,283 individuals from these 262 families were genotyped on 328
microsatellite markers. The MarshfieldMS data contain 234 EA,
77 AA and one mixed families, with a total of 1,442 individuals
genotyped on 394 microsatellite markers. 1,041,304 SNPs were
genotyped for 1,399 EA and 485 AA individuals in the CIDRSNP
GWAS. (Tables 4, 5 and 6).
With AA and mixed families excluded, we have 3,016 out of
3,567 EA individuals from 453 families genotyped on microsat-
ellite markers in the LinkageMS data. 471 of these individuals in
398 linkage families were selected for SNP genotyping (known as
the mutual individuals) (Table 6), including 41 individuals
without microsatellite genotyping data. For GWAS, from each
of these 398 families, one affected child (normally the proband)
was selected as the case and other biologically unrelated family
Figure 2. Combined pedigree structure used in inference. The pedigree has indtotal individuals and (mrkMS+mrkSNP) markers. Most individuals
have been genotyped on microsatellite markers. indcommon out of indtotal individuals are selected for SNP genotyping. Microsatellite and SNP markers
are mapped based on their genetic positions. Missing SNPs of (indtotal - indcommon) will be inferred by MERLIN –infer.
doi:10.1371/journal.pone.0063526.g002
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member(s) were used as the control. In total, 1,399 EA CIDRSNP
individuals consist of 847 cases and 552 controls. Figure 3 shows
the pedigree of one of the LinkageMS EA families (FAM_ID
20059). This family has four mutual individuals. Except for
proband #1, all the other three (#2, 9, and 13) selected for
GWAS are relatives by affinity to this family.
Marker cleaning & mapping. In order to match up the
genetic positions of all microsatellite and SNP markers, 38
microsatellite markers in Map03 and 58 microsatellite markers
in Marshfield were excluded because of their missing physical
positions. ,200,000 SNPs with low minor allele frequency (#5%)
were excluded. In consideration of any possible impact from
linkage disequilibrium (LD), we exclude ,1,500 SNPs that are
within 1,000 base pairs flanking each microsatellite marker. We
use equation (2) to create the common map for these microsatellite
and SNP markers. A comparison of the numbers of microsatellite
and SNP markers before and after cleaning is given in Table 6.
Figure 4 shows the distribution of these cleaned markers in EA
families. With these cleaned and mapped markers, we create new
pedigrees with the LinkageMS and CIDRSNP data combined
together. One combined pedigree has indtotal individuals (in rows)
with (mrkMS+mrkSNP) markers (in columns). Missing SNPs of (indtotal -
indcommon) individuals were inferred by MERLIN. (Figure 1).
dTDT and mantel-Haenszel test. In this study, we apply
both the dTDT and Mantel-Haenszel (MH) tests to the COGA
data. The MH test was first proposed by Mantel and Haenszel in
1959 [78]. The method has been widely applied to analysis of
contingency tables (normally 2 6 2) and comparison of results
from different treatments. In case-control studies, a 26 2 table is
typically used. The discrepancy between observed and expected
values in each cell from the table is evaluated by x2 test with one
degree of freedom. Comparatively, because the dTDT only takes
account of values of b and c, the test can be constructed by a 162
table instead. To maximally benefit from all sample data and
multiple studies, we extend the MH test to pool results on each
SNP from these two contingency tables in both case-control study
and dTDT. Calculation of each term in the MH test is shown in
Table 7. Having the Observed & Expected values and Variances
from case-control study and dTDT, terms in MH test can be
written as the sums of corresponding values these two tests. The
null hypothesis assumes no association between markers and
disease.
Results
Simulation
We separate the simulation results into nine groups that are
combinations of three disease models and three K values (0.01, 0.1
and 0.2). In each group there are 100,120 settings with different
R and f values. With each setting we generate 1,000 trios and
replicate the inference and dTDT procedures. Because of the large
number of these settings (1,320 in total), we attach the results as in
supplement tables. A plot of the log10 pvalueð Þfor these models is
shown in Figure 5. In the figure, graphs from the top row to the
bottom row represent the dominant, recessive and codominant
models respectively, and from left to right represent the results
with three different K values (0.01, 0.1 and 0.2). Each blue dot
corresponds to a/under that specific setting.
Because there are many factors interacting with each other, we
will start with a general comparison of different models then look
at the impact from one or two factors while constraining the others
constant.
In general, reading the values of log10 pvalueð Þfrom each
model, we find that a rare (K=0.01) recessive disease model
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produces higher power compared to common (K=0.1 or 0.2), co-
dominant or dominant disease models. Meanwhile, high R value
(0.9 or 1.0) also helps increase dTDT’s ability to detect signals.
This is because in a rare recessive case, markers with high LD to
the disease allele both parents are heterozygous and both transmit
the recessive risk allele to their offspring. Our findings from the
simulation validate what we already observed in the biological
phenomenon.
In the figure, each graph is broken down into four bins having
R=0.5, 0.7, 0.9 and 1.0. Interestingly, within each bin, when
log10 pvaluesð Þ are ordered by descending f11 (from 0.9K to 0.0)
and increasing f12 & f22 (from 1.1K to 1.0), it shows a noticeable
increasing trend as shown on the graphs. Meanwhile, when f22 is
small ( = 1.1K), the blue dots are close to the bottom line on each
graph. We note that in order to have enough power to detect the
signals, we need to have relatively distinguishable penetrances (i.e.
f cannot be too close to g) in the model. Indeed, there is no
information when all three penetrances are equal to K.
When we generate the trios, we use a roulette wheel algorithm
to assign SNPs to the children. This randomness is reflected on the
graphs as the dots spread in some irregular patterns. Reading the
graphs from left to right, we can see that with low prevalence
(K=0.01) the dots appear in clear clusters. Each cluster
corresponds to a specific f11 value. Taking the top left graph
(dominant with K=0.01) as an example, f11 changes in the order of
0.9K, 0.7K, 0.5K, 0.3K, 0.1K and 0.0. Within each cluster, f12 & f22
increase in the order of 1.1K, 0.5, 0.9 and 1.0. This clustering
holds true in the other two disease models (recessive and co-
dominant) when K is small (K=0.01) except some f11 valued
clusters are missing because combinations with invalid p were
excluded. In summary, the above observation indicates that f11 has
a higher impact to the power than f12 & f22 do in a rare disease
model. As the prevalence increases (K=0.1 and 0.2), the clustering
effect gradually disappears. In each R valued bin when K is large
(0.1 or 0.2), though the penetrances are sorted in the same order as
mentioned above, the dots represent certain continuity instead of
clustering. This shows that, in a common disease model, f11 is not
the only or the most effective factor as it is in a rare disease model.
Other factors start to interact with each other. Especially when
K=0.2 and R=1.0 (the fourth bin in the three graphs on the
right), the dots appear in clear fan-shaped sectors. This irregularity
can be partially explained by the sensitivity to randomness of the
model under such setting, i.e., small changes of the parameters can
have high impact on the results.
We can further see how the penetrances differ by looking at the
slope of the trend in each bin. Apparently as the value of R
increases across the bins, the slope of the trend also increases. This
is because when R is high (such as 0.9 and 1.0), the same degree of
lift in the penetrances will add more power and move/more
quickly to its next level compared to the situation when R is low
(such as 0.5). From another point of view, we can imagine these
slopes as the (first) derivatives of a convex function in terms of R.
On this convex curve, as R moves along to its rightmost end
(increases), the derivative of the function increases and the function
value (power) improves faster.
Application to Alcohol Dependence
In a recent work in a case-control study using GWAS data on
the COGA sample, Edenberg et al [79] identified the most
significant SNP rs10511260 on chromosome 3 with p-value
(P) = 3.461026. A cluster of SNPs was found in a region of
chromosome 11 with p-values ranging from 4.861025 to
6.961024. No single SNP showed genome-wide significance
(561028). In the following sections, we will compare our results
from dTDT on COGA data with these findings from Edenberg et
al’s work.
dTDT on COGA data. To apply the dTDT on each SNP
from COGA, we re-build the inferred pedigrees by extracting all
trio combinations in which every child in a trio must be affected
and at least one parent was genotyped on microsatellite markers.
Table 6. Summary of microsatellite and SNP markers in EA group before and after cleaning.
Total Number of Raw
microsatellite markers
Number of microsatellite markers after
cleaning (mrkMS)
Number of CIDR SNPs after cleaning
(mrkSNP)*
Map03MS EA 328 290 801,273
MarshfieldMS EA 394 336 801,286
*compared to 1,041,304 SNPs before cleaning.
doi:10.1371/journal.pone.0063526.t006
Figure 3. Pedigree of one Map03 family (FAM_ID 20059). Common individuals (#1, 2, 9 and 13, from left to right) are genotyped on both
microsatellite and SNP markers (circled in red). Box shadowed in upper left: AB, alcohol abuse; shadowed in upper left & right: AD, alcohol
dependence (DSM III-R Diagnosis). Box shadowed in lower left: PROB, probable; shadowed in lower left & right: DEF, definite (Feighner Diagnosis).
doi:10.1371/journal.pone.0063526.g003
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Because one family can have more than one affected child, the
parents can be found in more than one trio. For instance, the
family (FAM_ID 20059) as shown in Figure 3 has four affected
children (#18, 1, 5 and 12, from left to right). Mother (#30) was
genotyped on microsatellite markers. Therefore we have four trios
from this family. In total, 893 trios from 323 families with 1,654
individuals in the LinkageMS EA group were extracted and used to
build the trio-dosage pedigrees. 166 SNPs are found with p-values
,1024. This is compared to 93 SNPs at the same level in
Edenberg et al’s paper [79]. Several clusters of SNPs on
chromosome 7, 8 and 22 have p-values #1025. However, further
analysis with MH statistics does not yield consistent results with
dTDT. This may be primarily due to the relatively small sample
size used in dTDT and accuracy of the ‘‘–infer’’ program.
Combining case-Control study and dTDT. With dTDT
and case-control analysis applied to the LinkageMS and CIDRSNP
data respectively, we compute the p-values of MH test based on
calculations in Table 7. Figure 6 shows the Manhattan plots of –
log10P across all 23 chromosomes from the MH test. The most
significant SNP (rs11583322) on chromosome 1 gives a p-
value = 1.1061028 that meets the GWAS significance level. This
SNP lies in the gene Serine/Threonine Kinase 40 (STK40) that
connects pluripotency factor Oct4 to the Erk/MAPK pathway
controls extraembryonic endoderm differentiation [80]. Table 8
Figure 4. Distribution of cleaned microsatellite and SNP markers on 23 chromosomes in EA families. These markers are used in the
combined pedigrees for genotype inference. (a) distribution of microsatellite markers on 23 chromosomes in Map03 (blue) and Marshfield (red)
(overlapped); (b) distribution of SNPs on 23 chromosomes in Map03 and Marshfield. Because the difference of SNPs numbers in these two datasets is
trivial, we only display the distribution of SNPs in Map03.
doi:10.1371/journal.pone.0063526.g004
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Figure 5. –log10(P) distribution of nine disease models from the simulation results. Graphs from the top row to the bottom row represent
the dominant, recessive and codominant models respectively, and from left to right represent the results with three different K values (0.01, 0.1 and
0.2). Each blue dot corresponds to a –log10(p-value) under that specific setting. Every graph is broken down into four bins with R= 0.5, 0.7, 0.9 and 1.0.
Within each bin, the –log10(p-values) are ordered by descending f11 and increasing f12 & f22.
doi:10.1371/journal.pone.0063526.g005
Figure 6. Manhattan plot of –log10P from MH test across all 23 chromosomes for LinkageMS EA data. The dashed red line shows the
genome-wide significant level –log10(56 10
28) < 7.3. SNP rs11583322 has given –log10P < 8.1 above this level that lies in gene STK40.
doi:10.1371/journal.pone.0063526.g006
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lists the top SNPs with MH test p-values ,1025 and their
corresponding case-control study and dTDT p-values. From the
table we can see that the p-value of each SNP in the MH test is
approximately the product of p-values in the other two tests.
However, SNPs with high rankings by p-values in the MH test do
not systematically correspond to high rankings in the individual
tests. The p-values in the dTDT share the highest variance
(2.0161023) among the three tests because of the randomness
introduced by the inference procedure as well as the difference in
sample sizes across the tests. A larger sample size will likely
increase the power and generate more robust test results. In total,
we have 257 SNPs in 75 genes with p-values ,1024. 14 SNPs at
the same level of p-values are found in replication of Edenberg et
al’s study [79]. Four of these 14 SNPs have associated genes:
CSMD2 on chromosome 1, LZTS2 & PDZD7 on chromosome 10,
and Gcom1 on chromosome 15. There are 34 vs. 11 SNPs that
have p-values ,1025. Five SNPs across chromosome 1, 3, 9, 12
and 14 show p-values ,5.161027 which is more statistically
significant than the case-control analysis by Edenberg et al [79].
Our results also show clusters of SNPs by distance with p-values
,1025 (more than five such markers in one cluster) in genes
EXOC6B, FTO, NCAM2 and PPEF1 on chromosome 2, 5, 21 and
X, respectively.
Experimental Validation
Based on results from the MH test (5th column on Table 8), 19
out of the top 30 SNP markers were genotyped for 1,586
individuals from 220 Wave I & II families. We used the Sequenom
MassArray technology for SNP genotyping [81]. PCR primers,
extension primers, and multiplexing capabilities were determined
with Sequenom MassARRAY Assay Designer software v3.1.2.2.
Standard procedures were used to amplify PCR products;
unincorporated nucleotides were deactivated with shrimp alkaline
phosphatase. A single base pair extension step was completed with
the mass extension primer and the terminator (iPLEX). The
primer extension products were cleaned with resin and spotted
onto a silicon SpectroChip. The chip was scanned with a mass
spectrometry workstation (Bruker). The resulting genotype spectra
were analyzed with Sequenom SpectroTYPER software v3.4.
Because variant rs11583322 did not work well with the
Sequenom genotyping platform, we used the PrimerPicker
software [82] to design the assay and followed the protocol
described in KASPar SNP Genotyping System manual to run
PCR reaction with an ABI GeneAmp PCR System 9700 [83].
Genotypes were accessed using an ABI 7900 HT Fast Real-Time
PCR system. Because the genotypes are from linkage families, we
used the program UNPHASED [84] to perform a genetic
association analysis. Our colleagues in Allison Goate’s lab
implemented the above genotyping process. The author did the
final analyses of the genotypes. Results are shown in Table 8.
Discussion
Simulation
As shown above, we can see that simulation can be a powerful
tool to investigate many interactions between various factors and
help discover potential rules underlying these factors.
With slight modification of the above technique, we can use our
simulation to investigate how the dTDT is affected by population
stratification. Simulating different populations to have different
prevalences, we can choose two sets of trios using different allele
frequencies. Applying the dTDT to this combined set of trios, we
can test whether the power is lowered or heightened because of the
prevalence difference within the populations. Since there is no
information on phase of two markers in a trio, we have not
introduced the recombination frequency (h) in the simulation.
Tradeoff
When applying the dTDT to the alcohol dependence data from
COGA, nearly twice the number of SNPs (166 vs. 93) were found
having p-values ,1024. Further, to maximally make use of the
available sample data, we combine case-control study and dTDT
with the MH test. This potentially increases our sample size and
makes the method more robust to uncontrolled factors. As a result,
we have one signal in gene STK40 with p-value that attains a
genome-wide significance level. A large number of SNPs are found
having p-values ,1024. Several clusters of SNPs by distance with
p-values ,1025 are found in various genes across the genome.
Table 7. Calculations of Observed & Expected values, Variance, x2 test in Case-Control study, dTDT and MH test.
Case-Control study dTDT MH test
Structure Case Control NT
allele 1 allele 2 –
# allele
1 a1~2|#cs|fcs b1~2|#cn|fcn T
allele
1 – b2
# allele
2 c1~2|#cs{a1 d1~2|#cn{b1 allele 2 c2 –
Total (N) a1zb1zc1zd1 – a1zb1zc1zd1
Observed (O) a1(orc1) b2(orc2) (a1zb2)or(a1zc2)*
Expected (E) (a1zb1 )|(a1zc1 )
N
(b2zc2)
2
(a1zb1)|(a1zc1)
N
z (b2zc2)
2
Variance (a1zb1 )|(a1zc1 )|(c1zd1 )|(b1zd1 )
N2 (N{1)
(b2zc2)
4
(a1zb1)|(a1zc1)|(c1zd1)|(b1zd1 )
N2(N{1)
z (b2zc2 )
4
x2 test (O{E)2
V
(b2{c2)
2
(b2zc2)
(O{E)2
V
Number of Cases (#cs) = 847; Number of Controls (#cn) = 552; fcs: allele frequency in cases; fcn: allele frequency in controls; T is short for Transmitted; NT is short for Non-
Transmitted. b2=Sbi and c2=Sci. Using either a1 or c1 in Case-Control study will give the same results.
*equivalent to (c1zb2)or(c1zc2).
doi:10.1371/journal.pone.0063526.t007
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The Quantile-Quantile (Q-Q) plots are used in GWAS to assess
the inflation of FPRs by comparing the distribution of observed p-
values against the theoretical model distribution of expected p-
values [85]. In theory, without type I error arising from population
stratification or other artifacts, the Q-Q plot shall align with the
diagonal line. This is true if we use completely randomized data.
By comparing the distortion of the Q-Q plot of the test results
from this diagonal line, we can tell whether there are false positives
or other errors due to genotyping or imputation. Before we draw
any conclusion, we provide the Q-Q plots for results from all three
Case-Control, dTDT and MH tests on the COGA data (Figure
7). From the figure we can see that most of the observed p-values
from Case-Control and dTDT are along the diagonal line. We do
not observe significant distortion, i.e., type I error, in both tests.
On the other hand, the Q-Q plot of MH test lies above the
diagonal line. As stated earlier, both Case-Control and the dTDT
are not robust to the population stratification because of the
dependence of allele frequencies in the populations. MH test is
basically a combined statistic of these two tests. Though we have
increased the sample size in the combined test, we have reason to
believe that such sensitivity to population stratification has been
inflated in the MH test. This is a tradeoff that we need to pay
attention to in the future studies. However, this issue can be
partially addressed by restricting accurate genotypes based on the
imputation quality score (IQS) [86] (discussed below in Dealing with
errors).
Having the observed -log10 (p-value) along the diagonal line in
the Q-Q plots doesn’t mean these tests agree with each other. To
investigate the concordance among these three tests, we rank the
-log10 (p-value) from the dTDT (or MH test) and pick the top 100
Table 8. Top SNPs with p-values ,1025 from MH test, and corresponding genes and p-values from Case-Control study, dTDT,
Unphased association analysis, and IQS with threshold on dosage probabilities above 0.0 or 0.8.
SNP CHR Position
Associated
Gene
MH test p-
value
Case-Control
p-value
dTDT p-
value MAF
Unphased
Wave I&II
IQS
(.0) IQS (..8)
rs12116935 1 36,562,133 FAM176B 6.98E-06 6.56E-04 1.04E-03 0.38 6.77E-01 0.21 0.91 (395)
rs11583322 1 36,594,899 STK40 1.10E-08 7.39E-06 1.04E-04 0.38 8.54E-01 0.20 0.85 (345)
rs1932933 1 160,384,670 NOS1AP 5.82E-06 1.99E-04 4.24E-03 0.37 6.85E-01 0.22 0.95 (478)
rs10801629 1 196,110,990 4.13E-06 1.18E-04 9.62E-03 0.40 (482)
rs10922323 1 196,128,944 6.46E-06 1.52E-04 1.23E-02 0.40 9.54E-01 0.31 0.91 (550)
rs1850344 3 108,667,763 8.16E-06 1.33E-04 2.08E-02 0.38 1.13E-01 0.21 0.92 (350)
rs4384980 3 183,941,763 5.78E-07 9.17E-05 6.93E-04 0.42 4.46E-01 0.21 0.90 (405)
rs2857839 4 3,006,428 GRK4 6.60E-06 1.11E-03 5.56E-04 0.39 (471)
rs1801058 4 3,008,948 GRK4 6.48E-06 9.67E-04 6.57E-04 0.39 5.62E-01 0.22 0.89 (564)
rs2798303 4 3,010,385 GRK4 1.28E-06 2.17E-04 8.55E-04 0.42 8.24E-01 0.22 0.91 (615)
rs994029 9 88,565,134 1.98E-07 3.62E-04 1.18E-05 0.37 3.59E-01 0.21 0.89 (713)
rs2398236 10 5,321,159 9.07E-06 7.15E-04 1.96E-03 0.40 5.04E-01 0.22 0.90 (362)
rs9423593 10 5,322,349 8.32E-06 1.04E-03 5.20E-04 0.37 9.04E-01 0.22 0.89 (381)
rs7076488 10 5,323,008 2.13E-06 2.03E-04 1.49E-03 0.41 (562)
rs3781458 10 126,333,921 FAM53B 4.27E-06 2.70E-03 1.31E-05 0.37 (729)
rs3781452 10 126,345,119 FAM53B 6.86E-06 3.43E-03 1.81E-05 0.37 (449)
rs1503452 11 16,408,708 SOX6 3.21E-06 2.58E-04 1.80E-03 0.37 5.38E-02 0.22 0.89 (477)
rs3924047 11 70,507,506 SHANK2 8.77E-06 2.19E-04 1.04E-02 0.44 4.95E-01 0.21 0.87 (489)
rs4356270 12 90,843,346 8.42E-06 8.12E-06 1.91E-01 0.35 (370)
rs12427267 12 90,848,103 6.00E-07 6.04E-05 1.90E-03 0.38 2.15E-01 0.19 0.95 (403)
rs11106345 12 90,850,631 7.22E-06 8.83E-06 1.81E-01 0.35 (511)
rs10848190 12 129,767,988 5.43E-06 4.83E-04 2.36E-03 0.39 (327)
rs1035717 14 69,648,452 SLC8A3 6.36E-06 1.32E-03 2.19E-04 0.41 7.12E-01 0.23 0.95 (334)
rs4903712 14 77,685,346 1.67E-06 3.40E-05 1.79E-02 0.27 1.99E-03 0.29 0.92 (768)
rs17754467 14 77,692,276 5.54E-07 3.20E-06 4.50E-02 0.23 7.36E-02 0.20 0.87 (621)
rs1568447 17 70,348,607 4.08E-06 5.26E-04 1.13E-03 0.38 (623)
rs9901283 17 70,349,427 GRIN2C 9.31E-06 8.18E-04 1.67E-03 0.38 (397)
rs11652088 17 70,351,427 GRIN2C 3.50E-06 4.58E-04 1.00E-03 0.38 7.25E-01 0.16 0.82 (537)
rs8111589 19 50,726,398 OPA3 8.27E-06 7.50E-05 4.03E-02 0.44 6.08E-01 0.21 0.90 (443)
rs2830045 21 26,380,280 APP 6.31E-06 1.77E-03 2.22E-04 0.37 (396)
VARIANCE 9.09E-12 8.60E-07 2.01E-03
MEAN 5.04E-06 6.94E-04 1.71E-02
Markers without Unphased and IQS data were not genotyped through the experimental validation. Numbers in the brackets next to the IQS (.0.8) column are the
numbers of individuals who meet such restriction on that specific marker.
doi:10.1371/journal.pone.0063526.t008
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signals. Then we plot these values with their corresponding -log10
(p-value) from the other two tests (Figure 8. To dTDT the other
two are Case-Control and MH test; to MH test the other two are
Case-Control and dTDT). From the figure, we can see that the
concordance performs poorly among these tests. The top signals in
either dTDT or MH test do not appear in the top list from the rest
two tests as expected. There can be several reasons for this
discordance: (1) genotyping errors in both linkage and association
data; (2) inaccuracy of the imputation; (3) interference from
population stratification. The first two issues may be addressed
through experimental validation as discussed below. The last issue
requires additional design for the tests that we will discuss in
Conclusions.
Dealing with Errors
After correcting for multiple tests (p-value= 0.05/19= 0.0026),
SNP rs4903712 on chromosome 14 remained significant. This was
the seventh most significant SNP from the MH test. As discussed
above, there are several issues affecting the dependability of our
test results. As we saw from the Q-Q plots, signals from MH test
have been inflated because of double counting of the population
stratification factor. On the other hand, the genotyping and
imputation accuracy may be taken into account as well. To
address these issues, we compute the IQS for the listed top SNP
markers on Table 8 with and without setting a 0.8 threshold on
the dosage probabilities. We report the number of individuals who
meet such 0.8 threshold (in the last column, the numbers in the
brackets next to IQS with dosage probabilities.0.8). According to
the IQS, when we exclude the dosage probabilities that are below
0.8, the inference program performs very well and provides above
,0.90 IQS on average. The reason is that for dosage probabilities
that are lower than 0.8, there is too much uncertainty for the
program to impute, which not only heavily distorts the results
(poor specificity) but also makes it difficult to filter out true
Figure 7. QQ-plots of Case-Control, dTDT and MH tests.
doi:10.1371/journal.pone.0063526.g007
Figure 8. Line chart of top 100 signals from Case-Control, dTDT and MH tests. (a) line chart ranked by -log10 (p-value) from dTDT and its
corresponding -log10 (p-value) from the other two tests: Case-Control & MH test; (b) line chart ranked by -log10 (p-value) from MH test and its
corresponding -log10 (p-value) from the other two tests: Case-Control and dTDT.
doi:10.1371/journal.pone.0063526.g008
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positives (low sensitivity). However, there is always a tradeoff when
we enhance the accuracy. If we set a 0.8 threshold on dosage
probabilities, the sample size dramatically reduces from 1,586 to
326 (intersection set across all markers). We further apply dTDT
and MH test onto these 326 individuals with either the inferred or
genotyped data but do not find significant markers at a 1025 level
due to a small sample size (data not shown).
As above, the experimental validation shows that the accuracy
of the inference program can heavily impact the results of the
dTDT and MH tests. The disagreement of results from these two
tests on the real data could be attributed to several sources. First,
the sample size of informative data is small. In total, we have 3,567
individuals from 453 EA families included for inference calcula-
tion. Within all these individuals, only 471 individuals were
selected for SNP validation genotyping. This requires genotypes of
more than 85% of individuals to be estimated. In addition,
compared to the total number of SNPs, the number of
microsatellite markers is also trivial (722 vs. 1 million).
According to Table 8, though the sample size may be reduced,
we still recommend limiting dosage probabilities before genotyp-
ing. In our experience, a threshold at 0.7, 0.8 level can be a good
cut-off. A threshold lower than this level may contribute too much
noise and a threshold higher than this may reduce the sample size
significantly. Meanwhile, we suggest interpreting the dTDT
signals only after genotyping validation in order to lower the risk
of false positives.
Conclusions
Since the discovery of Mendel’s law, genetic research has been
challenged to identify genetic variants that contribute to human
diseases. Along with the development of genome sequencing
technologies, there have been impressive progresses within the
research community over the past decade. Numerous methodol-
ogies have been developed and many disease-associated genes
have been reported [87]. In this study, the work presented here
embraces the recent development and addresses some of the
research challenges in the field of genetic research. However, as we
have seen, despite the promises of the solution we provide, it also
prompts a great need to further investigate many of the issues we
have presented.
As discussed, traditional case-control studies on GWA often
include only unrelated individuals. By including family informa-
tion in the study, we can expect an increase in power for linkage
and association detection. On the other hand, because the
traditional TDT requires complete genotypic information from a
trio by measuring over-transmission of an allele from heterozygous
parents to the affected offspring, it may be less useful in trio data
like COGA where there are relatively few complete trios. To
overcome these limitations, in this project, we extend the original
TDT to the dTDT to accommodate dosage probabilities of a trio.
The trio-dosage sets can be inferred through programs like
MERLIN. Compared to a recent work from Edenberg et al, the
dTDT shows increased power to detect association.
Genotype inference allows us to evaluate the evidence for
association at the genetic markers that are not directly-genotyped.
It helps improve the power of individual scans and is of particular
usefulness for combining information from different studies such as
linkage and GWAS. However, the accuracy of genotype inference
may be impaired for the following reasons. First, because datasets
where subjects are genotyped on different platforms may have
different genotyping error rates, when we combine these datasets,
inference can be problematic. Second, genotype inference for large
datasets based on a small amount of shared information may
encounter too much uncertainty in the procedure. For a similar
reason, SNPs with low MAF may also have a higher chance of
being inferred inaccurately.
On the other hand, a major advantage of the TDT is that it is
not susceptible to population stratification. The dTDT is,
however, sensitive in that it depends on the marker allele
frequencies in the population. Because of this reason, when we
combine results from both Case-Control and dTDT, the MH test
potentially inflates errors due to population stratification. This can
be noticed in the Q-Q plot as we present in Figure 7.
In summary, as we inspect the reasons for having low
concordance among the tests as well as poor replication from
our test results to the experiment validation, we have the following
conclusions:
I. Because the linkage and GWAS data were genotyped on
different platforms, they may carry different genotyping
errors, which make it difficult to obtain genotype inference
accurately; inference across these platforms can generate
spurious associations;
II. Due to a great sparsity in the combined dataset, a large
number of the markers have to be inferred without sufficient
support from the common markers, which introduces too
much uncertainty in the inference;
III. Because of possible population stratification, combining
both the Case-Control and the dTDT to enhance the
sample size may introduce false positive signals.
As one solution, when we filter out poorly-inferred SNP markers
using IQS, we are able to removes thousands of false positives that
can be particularly useful for SNPs with low MAF and when
datasets are genotyped on different platforms. However, the
tradeoff is we have to exclude a good number of individuals from
our database in order to meet such restriction. But this can always
be an option when enough samples are available.
Despite this area for methodological development, our work
posits that the dTDT has considerable utility for linkage and
association testing. By exploiting family data with inference and
existing case-control information, the dTDT demonstrated here
has opened a new window to possible routes for the integration of
both population-based and family-based studies.
Future Direction
To address the sensitivity issue due to population stratification,
it is necessary to validate the SNP genotyping and perform a test
such as the PTDT to validate results and use a program such as
UNPHASED. This approach minimizes expense when the case/
control sample is derived from an existing family study in which
relatives have available DNA for typing. Moreover, we may
implement additional application to other populations such as
African Americans to compare findings with what we have from
the European Americans. This will require extending the
techniques described above.
We may explore using more of the family data instead of only
using SNPs. Other sources of information could be captured,
such as the copy number variants (CNVs) [88,89]. It is also
suggested that non-genetic risk factors tend to raise the attention
for complex traits and should also be incorporated into the
genetic studies. Meanwhile, it is likely that COGA will obtain
GWAS data in the relatives so that we can evaluate the efficiency
of inference versus having GWAS genotypes available. Power
calculation and sample size estimation of the new statistics are
needed for general use. Due to the uncertainty inherent to the
TDT Using Linkage and Association Detection
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inference procedure, we plan to develop better strategies for
generating dosage probabilities.
Finally, the dTDT should not be limited to dosage
probabilities from the inference programs only. As a perspec-
tive, the next-generation sequencing data will provide a
challenge using the method developed in this paper. Similar
methods can be used when pedigree members have a SNP
chip, and a subset has sequence data. Despite the discordance
and poor replication from our test results, we believe that
linkage can help identify regions of interest in conjunction with
association testing. Computational inference has helped us
reduce the experimental cost in that we may only need to do
sequencing on a limited number of family members. Keeping
this in mind, we need to implement appropriate selection of
the most informative families when we do genotyping. All these
future directions shall be promising and have potential to
inform the field.
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